Fidelity Investments
CCCC icon

Fidelity Investments’s C4 Therapeutics CCCC Stock Holding History

Fidelity Investments’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.92M Buy
1,175,723
+281,669
+32% +$1.05M ﹤0.01% 2542
2026
Q2 		$4.18M Buy
894,054
+621,686
+228% +$2.13M ﹤0.01% 2486
2026
Q1 		$716K Buy
272,368
+17,962
+7% +$42.3K ﹤0.01% 2983
2025
Q4 		$486K Buy
254,406
+43,058
+20% +$102K ﹤0.01% 3097
2025
Q3 		$469K Buy
211,348
+9,990
+5% +$24K ﹤0.01% 3054
2025
Q2 		$288K Buy
201,358
+7,608
+4% +$11.1K ﹤0.01% 3176
2025
Q1 		$310K Sell
193,750
-24,615
-11% -$73.4K ﹤0.01% 3077
2024
Q4 		$786K Buy
218,365
+32,424
+17% +$161K ﹤0.01% 2758
2024
Q3 		$1.06M Buy
185,941
+162,314
+687% +$977K ﹤0.01% 2581
2024
Q2 		$109K Sell
23,627
-13,661
-37% -$81.5K ﹤0.01% 3264
2024
Q1 		$305K Sell
37,288
-272
-0.7% -$2.11K ﹤0.01% 2879
2023
Q4 		$212K Sell
37,560
-83,605
-69% -$191K ﹤0.01% 2947
2023
Q3 		$225K Buy
121,165
+66,398
+121% +$203K ﹤0.01% 2858
2023
Q2 		$151K Sell
54,767
-335
-0.6% -$1.08K ﹤0.01% 3027
2023
Q1 		$173K Buy
55,102
+2,763
+5% +$16.3K ﹤0.01% 3032
2022
Q4 		$309K Sell
52,339
-5,181
-9% -$43K ﹤0.01% 2873
2022
Q3 		$504K Buy
57,520
+56,210
+4,291% +$584K ﹤0.01% 2780
2022
Q2 		$9.9K Sell
1,310
-597,971
-100% -$5.26M ﹤0.01% 4116
2022
Q1 		$14.5M Sell
599,281
-49,700
-8% -$1.21M ﹤0.01% 1946
2021
Q4 		$20.9M Hold
648,981
– – ﹤0.01% 1804
2021
Q3 		$29M Buy
648,981
+69,700
+12% +$2.98M ﹤0.01% 1666
2021
Q2 		$21.9M Buy
579,281
+240,894
+71% +$8.63M ﹤0.01% 1817
2021
Q1 		$12.5M Sell
338,387
-332,900
-50% -$13.2M ﹤0.01% 1962
2020
Q4 		$22.2M Buy
+671,287
New +$19.5M ﹤0.01% 1674

Other funds holding CCCC

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Silverarc Capital Management
Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Fidelity Investments's CCCC Position: Q3 2026 in Review

Fidelity Investments increased its C4 Therapeutics (CCCC) stake by 32% in Q3 2026, buying an estimated $1.05M and bringing the position to 1,175,723 shares worth $3.92M. The position accounts for ﹤0.01% of the portfolio, ranked #2542.

Fidelity Investments first reported a position in CCCC in Q4 2020 and has held it in 24 quarters since. The position peaked at $29M in Q3 2021. 80 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.

  • Fidelity Investments held 1,175,723 shares of C4 Therapeutics worth $3.92M as of Q3 2026.
  • Fidelity Investments bought 281,669 C4 Therapeutics shares in Q3 2026, an estimated $1.05M.
  • C4 Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #2542 holding.
  • Fidelity Investments first reported a position in C4 Therapeutics in Q4 2020 and has held it in 24 quarters since.
  • Fidelity Investments's C4 Therapeutics position peaked at $29M in Q3 2021.
  • 80 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.

Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.